We read with interest the previous issue of Critical Care, in which Zahar and colleagues [1] described Clostridium diffi cile infection (CDI) in patients during an intensive care unit (ICU) stay. Given some limitations of the authors' study, it is diffi cult to generalize from the results that CDI detected early will not aff ect ICU length of stay or mortality.
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Th e carrier eff ect, in which up to 20% of hospitalized patients can be chronic carriers of C. diffi cile, can aff ect results [2] . Unfortunately, chronic carriers are not identifi ed. Furthermore, the 72-hour cutoff for ICU-acquired C. diffi cile seems somewhat arbitrary as it can be acquired faster and some patients were admitted to the ICU within the fi rst 72 hours of hospital exposure [3] . In addition, variance in the fi rst-line treatment of acquired CDI and its eff ect on treatment outcomes is unreported.
Also, the detection immunoassay used a sensitivity well below (80%) those of the widely available cytotoxin neutralization assay (96%) and toxigenic culture (100%) [4] . Next, it is unclear whether the two populations were equally sick. Th e (younger) patients with diarrheal C. diffi cile were mechanically ventilated longer and received more proton pump inhibitors. Accordingly, unreported severity descriptors such as leukocytosis or renal insuffi ciency could infl uence mor tality outcomes. Furthermore, total hospital length of stay should be compared since C. diffi cile diarrhea alone does not necessitate admission to the ICU. Th e retrospective cohort trial is appro priate, but testing stronger strains of C. diffi cile, using higher-sensitivity detection methods, and tracking the entire length of stay would more accurately support the authors' conclusions. 
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We thank Nagella and colleagues for their kind comments about our study [1] and would like to address some of the issues they raise. As they pointed out, up to 20% of hospitalized patients can be chronic carriers. However, we wish to emphasize that, to avoid this bias, we restricted our study to patients with a new ICU-acquired CDI. We selected patients with CDI acquired after 72 hours as the exposed population. We agree that this arbitrary cut-point may have slightly decreased the incidence of ICU-acquired CDI. As stated by Zar and colleagues [5] , vancomycin is the treatment of choice for severe CDIs. As described in our paper, most patients received metronidazole as fi rst-line treatment, although most of them had severe CDI. Th is approach could have aff ected the mortality rate of patients with ICU-acquired CDI. However, the eff ects of CDI on mortality were strictly similar in subgroups receiving metronidazole or vancomycin as fi rst-line treatments. Owing to the 80% sensitivity of the test, some patients with CDI may have been falsely considered unexposed, leading to an artifi cial decrease in the over-risk of death associated with CDI. However, we checked all of the stools received by the lab during the same hospitalization, and no patients who were CDI-negative became CDI-positive during the same hospital stay. Furthermore, as stated in the paper, a secondary analysis, excluding patients who received metronidazole or vancomycin within 48 hours following a negative test, gave similar results. Finally, many factors may infl uence mortality and length of stay in the ICU [6] . We used modern statistical methods to take into account all measured time-fi xed and time-dependent charac teristics that may have acted as confounders. Of course, we cannot ensure that other unmeasured confounders did not exist, as they may exist in all cohort studies.
